
Just remember: Your coworkers will NOT be there for you in the last chapter of your life.
David Sinclair
10.4K posts

@davidasinclair
Professor researching why we age & how to reverse it. Author & host of Lifespan. Mission: Extend healthy life for all. Views are entirely his own. @joinlifespan

Just remember: Your coworkers will NOT be there for you in the last chapter of your life.

Acarbose is an alpha-glucosidase inhibitor prescription medicine that slows carbohydrate digestion. It increases median lifespan in mice around ~20% in males and smaller (~4–5%) in females New paper suggests its effects may not be by controlling sugar but by raising NAD! 🧵

Update: The first human partial reprogramming trial (OSK for glaucoma/NAION) has completed enrollment. Safety data expected Q4 2026. This is the first time epigenetic age reversal has been attempted in humans. We're tracking it →



Ancient cultures were extremely violent, not “peace-loving ecologists” at all!




Some thoughts on why it's so hard to find a cure for aging — tarkhov.ae/age-time-rever…

First drug ever shown to lengthen telomeres in a randomized trial. Henagliflozin, a diabetes drug, for 26 weeks. Results: - Treatment group: 90.5% had longer telomeres - Placebo group: 65.6% - Difference: statistically significant, p<0.01 This isn't a supplement study with 12 people. It's a randomized placebo-controlled trial of a drug millions already take for blood sugar. Telomere shortening is one of the 12 hallmarks of aging. Every decade, your telomeres lose about 14% of their length. This is the first time a pill has reversed that trajectory in a controlled experiment. SGLT2 inhibitors already extend life in heart failure patients. Now we might know one reason why.



Aging biotech has made TIME's "New Frontiers" list. @lifebiosciences is using Yamanaka factors, and the FDA just cleared their first-in-human trial for optic neuropathies. Partial epigenetic reprogramming is no longer theoretical. It's in human trials. time.com/article/2026/0…



Sirtuin 1 as an emerging exerkine in the aging process: unveiling its multifaceted biological roles "Taken together, these observations support the notion that SIRT1 functions as a potential exerkine, and understanding its role in exercise-induced adaptations offers new insights into non-pharmacological strategies to enhance longevity." link.springer.com/article/10.100…

